Methods	Randomised, double blind, parallel group, partial enriched enrolment. Initial dose titration before fixed dose for 450 mg only (8 weeks in total)
Participants	Fibromyalgia according to ACR classification and pain of at least 40/100 mm in week before randomisation. Mean age 49 years, 92% female, 93% white
Interventions	Pregabalin 150 mg daily, n = 132 Pregabalin 300 mg daily, n = 134 Pregabalin 450 mg daily, n = 132 Placebo daily, n = 131
Outcomes	Proportion of patients with ≥ 30% or ≥ 50% decrease in mean pain score between endpoint and baseline, and other outcomes
Notes	Oxford quality score: R2, D1, W1 = 4/5 Pfizer sponsored
Risk of bias
Item	Authors’ judgement	Description
Adequate sequence generation?	Yes	“computer generated code”
Allocation concealment?	Unclear	Not described
Blinding? All outcomes	Unclear	Stated to be double blind